Adherence: the Holy Grail?

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Abstract

Adherence to medicines has been identified as a key issue by the Royal Pharmaceutical Society of Great Britain, the WHO and, most recently, by the UK Academy of Medical Sciences. Estimates of adherence vary widely but are often reported to be as low as 50%. When a patient does not take their prescribed medicines as intended, they may not derive the expected outcomes. As well as implications for the individual patient, this can result in increased costs associated with patient hospitalisations or avoidable escalation in other costs of care. It may also result in unused medicines, the cost of which is estimated at £300 million per year in England alone.
Original languageEnglish
Pages (from-to)736-738
Number of pages3
JournalBMJ Quality & Safety
Volume25
Issue number10
Early online date3 Mar 2016
DOIs
Publication statusPublished - Oct 2016

Fingerprint

Costs and Cost Analysis
England
Hospitalization

Cite this

Adherence : the Holy Grail? / Bond, Christine M.

In: BMJ Quality & Safety, Vol. 25, No. 10, 10.2016, p. 736-738.

Research output: Contribution to journalEditorial

Bond, Christine M. / Adherence : the Holy Grail?. In: BMJ Quality & Safety. 2016 ; Vol. 25, No. 10. pp. 736-738.
@article{2e88513bb8b84ab88cbb09641865e599,
title = "Adherence: the Holy Grail?",
abstract = "Adherence to medicines has been identified as a key issue by the Royal Pharmaceutical Society of Great Britain, the WHO and, most recently, by the UK Academy of Medical Sciences. Estimates of adherence vary widely but are often reported to be as low as 50{\%}. When a patient does not take their prescribed medicines as intended, they may not derive the expected outcomes. As well as implications for the individual patient, this can result in increased costs associated with patient hospitalisations or avoidable escalation in other costs of care. It may also result in unused medicines, the cost of which is estimated at £300 million per year in England alone.",
author = "Bond, {Christine M}",
year = "2016",
month = "10",
doi = "10.1136/bmjqs-2015-004886",
language = "English",
volume = "25",
pages = "736--738",
journal = "BMJ Quality & Safety",
issn = "2044-5415",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Adherence

T2 - the Holy Grail?

AU - Bond, Christine M

PY - 2016/10

Y1 - 2016/10

N2 - Adherence to medicines has been identified as a key issue by the Royal Pharmaceutical Society of Great Britain, the WHO and, most recently, by the UK Academy of Medical Sciences. Estimates of adherence vary widely but are often reported to be as low as 50%. When a patient does not take their prescribed medicines as intended, they may not derive the expected outcomes. As well as implications for the individual patient, this can result in increased costs associated with patient hospitalisations or avoidable escalation in other costs of care. It may also result in unused medicines, the cost of which is estimated at £300 million per year in England alone.

AB - Adherence to medicines has been identified as a key issue by the Royal Pharmaceutical Society of Great Britain, the WHO and, most recently, by the UK Academy of Medical Sciences. Estimates of adherence vary widely but are often reported to be as low as 50%. When a patient does not take their prescribed medicines as intended, they may not derive the expected outcomes. As well as implications for the individual patient, this can result in increased costs associated with patient hospitalisations or avoidable escalation in other costs of care. It may also result in unused medicines, the cost of which is estimated at £300 million per year in England alone.

U2 - 10.1136/bmjqs-2015-004886

DO - 10.1136/bmjqs-2015-004886

M3 - Editorial

VL - 25

SP - 736

EP - 738

JO - BMJ Quality & Safety

JF - BMJ Quality & Safety

SN - 2044-5415

IS - 10

ER -